COST OF CONGESTIVE HEART FAILURE: THE CASE OF AN INSURED COLOMBIAN POPULATION

OBJECTIVES: To evaluate the direct inpatient costs of patients with Congestive Heart Failure (CHF) from an insured population enrolled to "De Todo Corazon" cardiovascular risk management program in Colombia, 2015. METHODS: Data were collected retrospectively from 283 patients with arterial...

Full description

Saved in:
Bibliographic Details
Published in:Value in health 2017-05, Vol.20 (5), p.A354
Main Authors: Sotomayor, M Carrasquilla, Alvis-Zakzuk, NJ, Zakzuk, J Alvis, de la Rosa, F Gomez, Martínez-Zarzuk, J, Ruiz, DV Moreno, Guzman, N Alvis
Format: Article
Language:English
Subjects:
Age differences
Cardiovascular disease
Cardiovascular diseases
Charges
Congestive heart failure
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Health care
Health services
Heart failure
High risk
Hospital costs
Hospitalization
Hypertension
Inpatient care
Insurance
Policy making
Risk factors
Risk groups
Risk management
Statistical analysis
Type 2 diabetes mellitus
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVES: To evaluate the direct inpatient costs of patients with Congestive Heart Failure (CHF) from an insured population enrolled to "De Todo Corazon" cardiovascular risk management program in Colombia, 2015. METHODS: Data were collected retrospectively from 283 patients with arterial hypertension (AH) or AH + type 2 diabetes mellitus (DM2) who suffered a CHF. These patients were enrolled into a cardiovascular risk management program of a state-subsidized insurance company (IC). The direct hospital costs were estimated through a top-down analysis from the third payer perspective. Costs were extracted based on billing and hospitalization records of the IC and converted to US dollars 2015. We used median and interquartile ranges (IQR) to describe costs by age group, risk level and risk factors. RESULTS: In total, 58.3% of the patients who suffered a CHF had both risk conditions (AH+DM2). According to the Framinghan risk score, 18.4% of patients were classified as low-risk (LR), 4.6% as medium-risk (MR), 32.9% as high-risk (HR) and 44.17% were unclassified. The median inpatient cost per patient with CHF by risk groups was: LR: US$2,256 (IQR $510-$4,998), MR: US$4,184 (IQR $895-$9,988) and HR: US$2,096 (IQR $935-$4,850). By risk group of factor, the median cost per patient with AH was:
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2017.05.005